Cadrenal Therapeutics, Inc. Common Stock (CVKD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a cash flow conversion efficiency ratio of -0.862x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.36 Million) by net assets ($2.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cadrenal Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Cadrenal Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Cadrenal Therapeutics, Inc. Common Stock (CVKD) total liabilities for a breakdown of total debt and financial obligations.
Cadrenal Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cadrenal Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Flour Mills Kepenos S.A.
AT:KEPEN
|
0.322x |
|
Breedon Group PLC
LSE:BREE
|
0.010x |
|
Nvni Group Limited Ordinary Shares
NASDAQ:NVNI
|
0.049x |
|
Thunderful Group AB
ST:THUNDR
|
-0.023x |
|
Golden Land Bhd
KLSE:7382
|
-0.063x |
|
Locality Planning Energy Holdings Ltd
AU:LPE
|
-0.754x |
|
Crown Point Energy Inc
V:CWV
|
-0.370x |
|
Voyageur Pharmaceuticals Ltd
V:VM
|
-0.295x |
Annual Cash Flow Conversion Efficiency for Cadrenal Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2024. For the full company profile with market capitalisation and key ratios, see CVKD market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.44 Million | $-7.36 Million | -0.989x | -115.49% |
| 2023-12-31 | $7.69 Million | $-3.53 Million | -0.459x | -311.46% |
| 2022-12-31 | $-5.55 Million | $-1.20 Million | 0.217x | -- |
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with… Read more